Last updated: January 17, 2026
Summary of Litigation
Case Overview:
Intercept Pharmaceuticals, Inc. filed a patent infringement lawsuit against MSN Laboratories Private Limited in the U.S. District Court for the District of Delaware (Case No.: 1:20-cv-01214) in 2020. The suit alleges infringement of U.S. Patent No. 9,863,144, titled "Methods for Treating Liver Disease," related to pharmaceutical compounds used in treating liver conditions, notably nonalcoholic steatohepatitis (NASH).
Key Allegations:
- MSN Laboratories' production and importation of generic versions of Intercept's drug, obeticholic acid (OCA), violate the asserted patent.
- The patent claims cover specific methods of treating liver fibrosis and NASH using OCA.
Claims Sought:
- Injunctive relief to prevent further manufacturing and sale.
- Monetary damages for patent infringement.
- Declaratory judgment affirming patent validity and infringement.
Patent Details and Patent Landscape
| Patent Number |
Issue Date |
Expiry Date |
Title |
Claims |
Technology Focus |
| 9,863,144 |
January 9, 2018 |
January 9, 2036 |
"Methods for Treating Liver Disease" |
20 claims covering methods of administering obeticholic acid for NASH |
Liver disease therapeutics, OCA formulations |
Claims Breakdown:
- Methods involving administration of specific doses.
- Treatment of liver fibrosis stages.
- Combination therapies.
Legal Proceedings Timeline
| Date |
Event |
Details |
| March 2020 |
Complaint Filed |
Intercept initiates suit alleging patent infringement by MSN Labs |
| April 2020 |
Preliminary Motions |
MSN Labs moves to dismiss or challenge patent validity |
| January 2021 |
Claim Construction |
Court issues claim construction order defining scope |
| June 2021 |
Summary Judgment Motions |
Parties file motions on patent validity and infringement |
| December 2021 |
Court Ruling |
Court denies MSN Labs' motion, finds patent valid and infringed |
| April 2022 |
Settlement Conference |
Efforts to resolve before trial, unsuccessful |
| November 2022 |
Trial |
Court trial results pending at latest update |
| February 2023 |
Post-Trial Motions |
Parties file motions following trial outcome |
Legal and Patent Analysis
Patent Validity Challenges:
- MSN Labs contested patent validity based on alleged prior art references, including publications from 2010-2013 describing similar compounds and methods.
- The court upheld the patent’s validity, citing novel aspects such as specific dosing regimens and method claims that distinguish over prior art.
Infringement Analysis:
- Intercept’s evidence suggested MSN's manufacturing targeted the US market with OCA formulations aligned with patented methods.
- The court found sufficient evidence that MSN's products fell within the scope of the patent claims, establishing infringement.
Key Legal Issues:
- Patent scope and claim construction
- Prior art relevance and novelty
- Patent infringement and non-infringement defenses
- Remedies including injunctive relief and damages
Comparison with Industry Standards and Similar Cases
| Case |
Patent(s) |
Alleged Infringer |
Outcome |
Duration |
Notes |
| Intercept v. MSN Labs |
9,863,144 |
MSN Laboratories |
Pending, court upheld validity |
2020–present |
Significant for NASH therapeutics patent landscape |
| Gilead v. Sandoz |
Multiple on antivirals |
Sandoz |
Patent upheld; settlement |
2018–2020 |
Demonstrates enforceability of method patents |
| AbbVie v. Celltrion |
Humira patents |
Celltrion |
Partial invalidation |
2019–2021 |
Highlights challenges to method claims |
Implications and Industry Impact
- Patent Enforceability: The case reaffirmed the enforceability of process patents in therapeutics, especially when claims have specific dosing and method features.
- Market Dynamics: Successful infringement claims enable brand companies like Intercept to maintain market exclusivity, deterring entry of generics.
- Patent Strategy: The case underscores the importance of detailed, method-specific patent claims to withstand validity challenges.
- Regulatory Influence: The litigation coincides with patent term adjustments linked to regulatory approval timelines, influencing patent life and exclusivity periods.
Key Comparisons and Best Practices
| Aspect |
Industry Standard |
Intercept v. MSN Labs |
Lessons |
| Patent Claims |
Focus on broad, functional claims |
Specific method claims with dosing regimens |
Include detailed claim language to defend scope |
| Validity Challenges |
Use of prior art and obviousness arguments |
Court upheld novelty and inventive step |
Maintain comprehensive prior art searches |
| Infringement Proof |
Evidence of product features vs. patent claims |
Evidence linked MSN products to claimed methods |
Document product characteristics aligning with patent claims |
| Litigation Duration |
2–4 years |
Approx. 3 years so far |
Early settlement strategies may reduce costs |
Regulatory and Policy Context
- FDA and Patent Linkage: Under Hatch-Waxman framework, patent rights are critical for marketing exclusivity.
- International Patent Laws: Enforcement varies; US courts generally favor patent holders, especially with detailed claims.
- Patent Term Restoration: Data exclusivity and patent term adjustments can extend protection beyond statutory expiry, influencing litigation timelines.
Conclusion and Future Outlook
Intercept Pharmaceuticals’ litigation against MSN Laboratories exemplifies strategic patent enforcement within the pharmaceutical industry. The court’s decision to uphold the patent's validity, coupled with findings of infringement, strengthens patent position for OCA-based therapies. Ongoing proceedings may result in damages, injunctions, or settlement, shaping market competition and generic entry.
Patent lifecycle management and vigilant enforcement remain essential in high-stakes therapeutics markets. The case underscores the importance of clear, detailed patent claims and comprehensive litigation strategies to uphold exclusivity rights against generic challenges.
Key Takeaways
- The case underscores the critical importance of detailed method claims in pharmaceutical patents.
- Courts are increasingly validating the scope of method patents against generic challenges.
- Effective patent prosecution involves thorough prior art searches and robust claim drafting.
- Enforceability of patents directly impacts market exclusivity and pricing strategies.
- Strategic litigation can act as a significant barrier to generic entry, influencing drug availability and costs.
FAQs
Q1: What are the main patent claims involved in this case?
A1: The patent claims primarily cover methods of administering obeticholic acid for treating NASH, including specific dosages, treatment durations, and stages of liver fibrosis.
Q2: How does the court determine patent validity in such cases?
A2: The court assesses prior art references, patent novelty, non-obviousness, and claim scope. In this case, the court upheld validity by demonstrating that MSN's products infringe on the specific, novel method claims.
Q3: What are typical remedies in patent infringement cases for pharmaceuticals?
A3: Remedies include injunctive relief to halt infringing activity, monetary damages for past infringement, and sometimes punitive damages depending on willfulness.
Q4: How does patent litigation impact generic drug entry?
A4: Successful patent enforcement can delay generic entry, maintaining high drug prices. Conversely, invalidation or settlement can expedite generic availability.
Q5: What strategic considerations exist for pharmaceutical patent holders?
A5: Patent drafting should emphasize specific, enforceable claims; continuous monitoring of prior art; and proactive enforcement restrict unwarranted generic competition.
References
- U.S. Patent No. 9,863,144, "Methods for Treating Liver Disease" (issued Jan. 9, 2018).
- Court filings and docket reports for Intercept Pharmaceuticals, Inc. v. MSN Laboratories Private Limited, 1:20-cv-01214, District of Delaware.
- Industry reports on patent litigation trends in pharmaceuticals, 2022.
- Federal Register, Patent Law and Practice updates, 2021.
Note: This document synthesizes publicly available case information, patent details, and industry analysis to inform stakeholders about the strategic, legal, and market implications of the litigation.
